Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Laura Rosiñol Dachs, Carmen Montes Gaisán, Gabriela Bustamante, Sebastián Garzón López, Esther González García, Ernesto Pérez Persona, Verónica González-Calle, Maialen Sirvent Auzmendi, José Maria Arguiñano Pérez, Yolanda González Montes, Rafael Ríos Tamayo, Dunia de Miguel Llorente, Luis Palomera Bernal, Antonia Sampol Mayol, Carmen Couto Caro, Marta Grande, Alonso Fernández-Nistal, Andrea Naves & Enrique M. Ocio San Miguel. (2023) Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study. Leukemia & Lymphoma 64:11, pages 1847-1856.
Read now
Read now
Pasquale Niscola, Laura Scaramucci & Fabio Efficace. (2019) Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma. Expert Review of Hematology 12:9, pages 703-705.
Read now
Read now
Paul G. Richardson, Sonja Zweegman, Elizabeth K. O’Donnell, Jacob P. Laubach, Noopur Raje, Peter Voorhees, Renda H. Ferrari, Tomas Skacel, Shaji K. Kumar & Sagar Lonial. (2018) Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy 19:17, pages 1949-1968.
Read now
Read now
Articles from other publishers (17)
Ramzi Shawahna, Riad Amer, Husam Salameh, Abdul-Rahman Shawahna, Mohmmad Aljondy & Mohmmad Zain-Aldain. (2023) Predictors of health-related quality of life of the patients treated for MM: the first study in the Palestinian healthcare system. Annals of Hematology 102:12, pages 3543-3554.
Crossref
Crossref
Hayley Beer, Holly Chung, Simon J Harrison, Hang Quach, Rebecca Taylor-Marshall, Laura Jones & Meinir Krishnasamy. (2023) Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study. Clinical Lymphoma Myeloma and Leukemia 23:7, pages 505-514.
Crossref
Crossref
Nitya Nathwani, Jill Bell, Dasha Cherepanov, France Ginchereau Sowell, Rachel Shah, Kelly McCarrier & Parameswaran Hari. (2022) Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. Supportive Care in Cancer 30:7, pages 5859-5869.
Crossref
Crossref
Juliana Todaro, Polianna Mara Rodrigues de Souza, Marci Pietrocola, Fernanda da Cunha Vieira, Nazaré Solange da Silva Amaro, Jandey da Gloria Bigonha, José Belém de OliveiraNetoNeto & Auro del Giglio. (2022) Cross-cultural translation and adaptation of Functional Assessment of Cancer Therapy – Multiple Myeloma tool – MM1 and LEU3 – for Portuguese. Einstein (São Paulo) 20.
Crossref
Crossref
Monika Engelhardt, Gabriele Ihorst, Moushmi Singh, Achim Rieth, Grèce Saba, Marine Pellan & Andrea Lebioda. (2021) Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. Clinical Lymphoma Myeloma and Leukemia 21:2, pages e160-e175.
Crossref
Crossref
Xiaozhe Li, Junru Liu, Meilan Chen, Jingli Gu, Beihui Huang, Dong Zheng & Juan Li. (2020) Health‐related quality of life of patients with multiple myeloma: A real‐world study in China. Cancer Medicine 9:21, pages 7896-7913.
Crossref
Crossref
M Graça Pereira, Isa Silva, Marta Pereira, Sara Faria, Bruna Silva, Sara Monteiro & Gabriela Ferreira. (2018) Unmet needs and quality of life in multiple myeloma patients. Journal of Health Psychology 25:10-11, pages 1717-1731.
Crossref
Crossref
Katja Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda & Hartmut Goldschmidt. (2019) Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. Quality of Life Research 29:1, pages 69-79.
Crossref
Crossref
Janet A. Parsons, Nicole R. Greenspan, Natalie A. Baker, Chris McKillop, Lisa K. Hicks & Olivia Chan. (2019) Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer 19:1.
Crossref
Crossref
M. Graça Pereira, Gabriela Ferreira, Marta Pereira, Sara Faria, Rosário Bacalhau, Sara Monteiro, Bruna Fernandes & Margarida Vilaça. (2019) Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ‐MY20) in Portuguese myeloma patients. European Journal of Cancer Care 28:5.
Crossref
Crossref
Crystal Antoine-Pepeljugoski & Marc Justin Braunstein. (2019) Management of Newly Diagnosed Elderly Multiple Myeloma Patients. Current Oncology Reports 21:7.
Crossref
Crossref
Barry D. Hock, Katie S. Mulholland, Peter Ganly, Judith L. McKenzie, John F. Pearson & Sean A. MacPherson. (2019) Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal 49:5, pages 598-606.
Crossref
Crossref
Xavier Leleu, Tamas Masszi, Nizar J. Bahlis, Luisa Viterbo, Bartrum Baker, Peter Gimsing, Vladimir Maisnar, Olga Samoilova, Laura Rosiñol, Christian Langer, Kevin Song, Tohru Izumi, Charles Cleeland, Deborah Berg, Huamao Mark Lin, Yanyan Zhu, Tomas Skacel, Philippe Moreau & Paul G. Richardson. (2018) Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. American Journal of Hematology 93:8, pages 985-993.
Crossref
Crossref
Shaloo Gupta, Safiya Abouzaid, Ryan Liebert, Kejal Parikh, Brian Ung & Aaron S. Rosenberg. (2018) Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 18:3, pages 210-218.
Crossref
Crossref
Fiona Kiely, Alison Cran, Deirdre Finnerty & Tony O’Brien. (2016) Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment. American Journal of Hospice and Palliative Medicine® 34:7, pages 671-676.
Crossref
Crossref
Nicolas Kint & Michel Delforge. (2016) Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?. Journal of Geriatric Oncology 7:5, pages 383-389.
Crossref
Crossref
Don RobinsonJrJr, Dixie‐Lee Esseltine, Antoine Regnault, Juliette Meunier, Kevin Liu & Helgi Velde. (2016) The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials. British Journal of Haematology 174:3, pages 368-381.
Crossref
Crossref